Article
New therapeutic targets in pancreatic cancer.
Cancer treatment reviews - 1 Dec 2019
Lai Eleonora, Puzzoni Marco, Ziranu Pina, Pretta Andrea, Impera Valentino, Mariani Stefano, Liscia Nicole, Soro Paolo, Musio Francesca, Persano Mara, Donisi Clelia, Tolu Simona, Balconi Francesca, Pireddu Annagrazia, Demurtas Laura, Pusceddu Valeria, Camera Silvia, Sclafani Francesco, Scartozzi Mario
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival. Of all newly diagnosed patients, only about 20% can benefit from a potentially curative surgical resection, the remaining 80% presenting with unresectable locally advanced (LAPC) or metastatic (MPC) disease. Currently, there are limited therapeutic options for LAPC and MPC patients. Furthermore, despite intensive research efforts to better...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.